(PharmaNewsWire.Com, June 23, 2017 ) Latin America attention deficit hyperactivity disorder (ADHD) therapeutics market is expected to reach USD 1.05 billion by 2020 from USD 0.63 billion in 2015, growing at a CAGR of 10.90% during the forecast period 2015-2020.
Attention deficit hyperactivity disorder (ADHD), is one of the most common neurological/psychiatric disorders among children and adolescents. ADHD is commonly observed in children (above 12 years age) as compared to adolescents. ADHD is also described as hyperkinetic disorder/ attention deficit disorder or neuropsychiatric disorder. The exact cause for the ADHD is not clear but, expected to be resulted due to genetic factors and environmental influences. ADHD results in improper functioning of nervous system that led to attention deficit and hyperactivity/impulsiveness condition. ADHD is characterized by certain symptoms include easy distraction & striving to maintain focus on one task, unable to remember things, impatience, and being continuously in motion, among others. The symptoms of attention deficit hyperactivity disorder (ADHD) are controlled by different modalities such as medication (stimulants-amphetamines; non-stimulants-atomoxetine), psychotherapy (behavior therapy, cognitive behavioral therapy), and education/training (parent management training, family training).
Growing number of learning disability patients, rising number of treatment solutions, and government initiatives towards the adoption of innovative neurological disorders therapeutics are some of the major factors driving the growth of attention-deficit hyperactivity disorder (ADHD) therapeutics market in Latin America. However, low adoption of attention deficit hyperactivity disorder therapeutics and requirement of high cost to maintain longer medications for the treatment of ADHD are some of the factors restraining the growth of attention deficit hyperactivity disorder (ADHD) therapeutics market in Latin America.
Latin America attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented based on medication, psychotherapy, and education or training. Medication involves stimulants and non-stimulants. Medication by stimulants comprises of amphetamines, methylphenidate, dextroamphetamine, and dexmethylphenidate, whereas medication by non-stimulants comprises of atomoxetine, bupropion, and guanfacine. Psychotherapy involves behavior therapy, cognitive behavioral therapy, interpersonal psychotherapy, and family therapy. Education or training involves parent management training, social skills training, and school-based interventions.
On the basis of geographical areas, Latin America attention deficit hyperactivity disorder (ADHD) therapeutics market is segmented as Brazil, Argentina, and Mexico.
The key players in attention deficit hyperactivity disorder (ADHD) therapeutics market such as, Shire plc (Ireland), Neos Therapeutics, Inc. (U.S.), Eli Lilly and Company (U.S.), Pfizer Inc. (U.S.), Alcobra Ltd. (Israel), Supernus Pharmaceuticals, Inc. (U.S.), Noven Pharmaceuticals, Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson (U.S.), and Curemark, LLC. (U.S.).
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
